Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $10

奧本海默控股維持Editas Medicine(EDIT.US)持有評級，下調目標價至10美元

moomoo資訊 · 2024/10/24 18:31 · 評級/大行評級

Oppenheimer analyst Jay Olson maintains $Editas Medicine (EDIT.US)$ with a hold rating, and adjusts the target price from $12 to $10.

According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.

AnalystRecentRatingAutoNews_211643_20241023_ca28d653a12aaba4dd35e4ddd0ccedbd16ec8f90_1729773080832376_mm_en

Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:

The firm believes that Editas Medicine's shift towards an in vivo SCD approach and the decision to partner out reni-cel may be a more strategic allocation of its expertise and resources, potentially leading to greater value creation, following the successful preclinical in vivo editing of HSPCs.
Editas Medicine has presented initial data from its in vivo approach, which involves the targeted lipid nanoparticle delivery to edit hematopoietic stem cells with the CRISPR-Cas12a enzyme. Alongside this, the company has expressed its intention to form global partnerships for reni-cel, prioritizing its resources on in vivo programs. Despite the promising early in vivo data, there is an expectation that investors may find it challenging to place significant value on a platform at such an initial stage of development.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

奧本海默控股分析師Jay Olson維持$Editas Medicine (EDIT.US)$持有評級，並將目標價從12美元下調至10美元。

根據TipRanks數據顯示，該分析師近一年總勝率為38.6%，總平均回報率為12.4%。

AnalystRecentRatingAutoNews_211643_20241023_ca28d653a12aaba4dd35e4ddd0ccedbd16ec8f90_1729773080832376_mm_tc

此外，綜合報道，$Editas Medicine (EDIT.US)$近期主要分析師觀點如下：

該公司認爲，繼HSPC的臨床前活體編輯成功之後，Editas Medicine向體內SCD方法的轉變以及與reni-cel合作的決定可能是其專業知識和資源的更具戰略性的配置，有可能帶來更大的價值創造。
Editas Medicine已經提供了其體內方法的初步數據，該方法涉及靶向脂質納米顆粒輸送，使用CRISPR-Cas12a酶編輯造血幹細胞。除此之外，該公司還表示打算與reni-cel建立全球合作伙伴關係，將其資源優先用於體內項目。儘管早期的活體數據令人鼓舞，但預計投資者可能會發現在開發的初始階段對平台進行重大估值具有挑戰性。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $10

Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $10

風險及免責聲明

聲明